COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer

Cong Zeng; John P. Evans; Karthik Chakravarthy; Panke Qu; Sarah Reisinger; No Joon Song; Mark P. Rubinstein; Peter G. Shields; Zihai Li; Shan Lu Liu

doi:10.1016/j.ccell.2021.12.014

COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer

Cong Zeng
, John P. Evans
, Karthik Chakravarthy
, Panke Qu
, Sarah Reisinger
, No Joon Song
, Mark P. Rubinstein
, Peter G. Shields
, Zihai Li
, Shan Lu Liu

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	117-119
Number of pages	3
Journal	Cancer Cell
Volume	40
Issue number	2
DOIs	https://doi.org/10.1016/j.ccell.2021.12.014
State	Published - Feb 14 2022

Access to Document

10.1016/j.ccell.2021.12.014

Cite this

@article{6753454ead3c4397b20b49e0996d7c5b,

title = "COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer",

author = "Cong Zeng and Evans, \{John P.\} and Karthik Chakravarthy and Panke Qu and Sarah Reisinger and Song, \{No Joon\} and Rubinstein, \{Mark P.\} and Shields, \{Peter G.\} and Zihai Li and Liu, \{Shan Lu\}",

note = "Funding Information: We thank members of the Liu lab, including Yi-Min Zheng and Julia Faraone, for sharing reagents and discussion. Additonal gratitude is extended toward Kevin Weller, Jamie Hamon, Donna Bucci, Kelsi Reynolds, Mohamed Yusuf, Robert Davenport, and Taylor Chatlos from the Immune Monitoring and Discovery Platform of the Pelotonia Institute for Immuno-Oncology for assistance in sample collection and discussion. We also thank members of the Li lab, including Chelsea Bolyard, Weiwei Liu, and Yi Wang, and members of the Rubinstein Lab, including Madison Sikorski, Joseph Azar, Rachael Teodorescu, Ian Carmody, Selah McKenney, and Kayla Hudson, for assistance in sample processing. Finally, we would like to thank the NIH AIDS Reagent Program and BEI Resources for supplying important reagents that made this work possible. This work was supported by a fund provided by an anonymous private donor to Ohio State University to S.-L.L. S.-L.L. was additionally supported in part by NIH grant R01 AI150473 . Z.L. was supported by the Ohio State University Comprehensive Cancer Center Cancer Center Support Grant ( P30CA016058 ) and multiple NIH grants ( R01 DK105033 , R01 AI077283 , R01 CA213290 , P01 CA186866 , R01 CA255334 , and P30 CA016058 ). P.G.S. was supported by multiple NIH grants, including NCI P30 CA016058 . S.R. and Z.L. were supported by the Peletonia Institute for Immune-Oncology . The Pelotonia Institute for Immuno-Oncology (PIIO) is funded in part by the Pelotonia community and the Ohio State University Comprehensive Cancer Center (OSUCCC) ( P30CA016058 ). In addition, support from the OSUCCC Shared Resources, including the Flow Cytometry and Clinical Treatment Unit and the Clinical Trials Processing Laboratory, is greatly appreciated. Funding Information: We thank members of the Liu lab, including Yi-Min Zheng and Julia Faraone, for sharing reagents and discussion. Additonal gratitude is extended toward Kevin Weller, Jamie Hamon, Donna Bucci, Kelsi Reynolds, Mohamed Yusuf, Robert Davenport, and Taylor Chatlos from the Immune Monitoring and Discovery Platform of the Pelotonia Institute for Immuno-Oncology for assistance in sample collection and discussion. We also thank members of the Li lab, including Chelsea Bolyard, Weiwei Liu, and Yi Wang, and members of the Rubinstein Lab, including Madison Sikorski, Joseph Azar, Rachael Teodorescu, Ian Carmody, Selah McKenney, and Kayla Hudson, for assistance in sample processing. Finally, we would like to thank the NIH AIDS Reagent Program and BEI Resources for supplying important reagents that made this work possible. This work was supported by a fund provided by an anonymous private donor to Ohio State University to S.-L.L. S.-L.L. was additionally supported in part by NIH grant R01 AI150473. Z.L. was supported by the Ohio State University Comprehensive Cancer Center Cancer Center Support Grant (P30CA016058) and multiple NIH grants (R01 DK105033, R01 AI077283, R01 CA213290, P01 CA186866, R01 CA255334, and P30 CA016058). P.G.S. was supported by multiple NIH grants, including NCI P30 CA016058. S.R. and Z.L. were supported by the Peletonia Institute for Immune-Oncology. The Pelotonia Institute for Immuno-Oncology (PIIO) is funded in part by the Pelotonia community and the Ohio State University Comprehensive Cancer Center (OSUCCC) (P30CA016058). In addition, support from the OSUCCC Shared Resources, including the Flow Cytometry and Clinical Treatment Unit and the Clinical Trials Processing Laboratory, is greatly appreciated. The authors declare no competing interests.",

year = "2022",

month = feb,

day = "14",

doi = "10.1016/j.ccell.2021.12.014",

language = "English",

volume = "40",

pages = "117--119",

journal = "Cancer Cell",

issn = "1535-6108",

number = "2",

}

TY - JOUR

T1 - COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer

AU - Zeng, Cong

AU - Evans, John P.

AU - Chakravarthy, Karthik

AU - Qu, Panke

AU - Reisinger, Sarah

AU - Song, No Joon

AU - Rubinstein, Mark P.

AU - Shields, Peter G.

AU - Li, Zihai

AU - Liu, Shan Lu

N1 - Funding Information: We thank members of the Liu lab, including Yi-Min Zheng and Julia Faraone, for sharing reagents and discussion. Additonal gratitude is extended toward Kevin Weller, Jamie Hamon, Donna Bucci, Kelsi Reynolds, Mohamed Yusuf, Robert Davenport, and Taylor Chatlos from the Immune Monitoring and Discovery Platform of the Pelotonia Institute for Immuno-Oncology for assistance in sample collection and discussion. We also thank members of the Li lab, including Chelsea Bolyard, Weiwei Liu, and Yi Wang, and members of the Rubinstein Lab, including Madison Sikorski, Joseph Azar, Rachael Teodorescu, Ian Carmody, Selah McKenney, and Kayla Hudson, for assistance in sample processing. Finally, we would like to thank the NIH AIDS Reagent Program and BEI Resources for supplying important reagents that made this work possible. This work was supported by a fund provided by an anonymous private donor to Ohio State University to S.-L.L. S.-L.L. was additionally supported in part by NIH grant R01 AI150473 . Z.L. was supported by the Ohio State University Comprehensive Cancer Center Cancer Center Support Grant ( P30CA016058 ) and multiple NIH grants ( R01 DK105033 , R01 AI077283 , R01 CA213290 , P01 CA186866 , R01 CA255334 , and P30 CA016058 ). P.G.S. was supported by multiple NIH grants, including NCI P30 CA016058 . S.R. and Z.L. were supported by the Peletonia Institute for Immune-Oncology . The Pelotonia Institute for Immuno-Oncology (PIIO) is funded in part by the Pelotonia community and the Ohio State University Comprehensive Cancer Center (OSUCCC) ( P30CA016058 ). In addition, support from the OSUCCC Shared Resources, including the Flow Cytometry and Clinical Treatment Unit and the Clinical Trials Processing Laboratory, is greatly appreciated. Funding Information: We thank members of the Liu lab, including Yi-Min Zheng and Julia Faraone, for sharing reagents and discussion. Additonal gratitude is extended toward Kevin Weller, Jamie Hamon, Donna Bucci, Kelsi Reynolds, Mohamed Yusuf, Robert Davenport, and Taylor Chatlos from the Immune Monitoring and Discovery Platform of the Pelotonia Institute for Immuno-Oncology for assistance in sample collection and discussion. We also thank members of the Li lab, including Chelsea Bolyard, Weiwei Liu, and Yi Wang, and members of the Rubinstein Lab, including Madison Sikorski, Joseph Azar, Rachael Teodorescu, Ian Carmody, Selah McKenney, and Kayla Hudson, for assistance in sample processing. Finally, we would like to thank the NIH AIDS Reagent Program and BEI Resources for supplying important reagents that made this work possible. This work was supported by a fund provided by an anonymous private donor to Ohio State University to S.-L.L. S.-L.L. was additionally supported in part by NIH grant R01 AI150473. Z.L. was supported by the Ohio State University Comprehensive Cancer Center Cancer Center Support Grant (P30CA016058) and multiple NIH grants (R01 DK105033, R01 AI077283, R01 CA213290, P01 CA186866, R01 CA255334, and P30 CA016058). P.G.S. was supported by multiple NIH grants, including NCI P30 CA016058. S.R. and Z.L. were supported by the Peletonia Institute for Immune-Oncology. The Pelotonia Institute for Immuno-Oncology (PIIO) is funded in part by the Pelotonia community and the Ohio State University Comprehensive Cancer Center (OSUCCC) (P30CA016058). In addition, support from the OSUCCC Shared Resources, including the Flow Cytometry and Clinical Treatment Unit and the Clinical Trials Processing Laboratory, is greatly appreciated. The authors declare no competing interests.

PY - 2022/2/14

Y1 - 2022/2/14

UR - https://www.scopus.com/pages/publications/85123858400

U2 - 10.1016/j.ccell.2021.12.014

DO - 10.1016/j.ccell.2021.12.014

M3 - Letter

C2 - 34986328

AN - SCOPUS:85123858400

SN - 1535-6108

VL - 40

SP - 117

EP - 119

JO - Cancer Cell

JF - Cancer Cell

IS - 2

ER -

COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer

Access to Document

Other files and links

Cite this